

# The transport barrier in intraperitoneal therapy

American Journal of Physiology - Renal Physiology

288, F433-F442

DOI: [10.1152/ajprenal.00313.2004](https://doi.org/10.1152/ajprenal.00313.2004)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Human eNOS gene delivery attenuates cold-induced elevation of blood pressure in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H1161-H1168.	1.5	28
3	Peritoneal Ultrafiltration: Mechanisms and Measures. , 2006, 150, 28-36.		16
4	Molecular chaperone $\beta$ -crystallin prevents detrimental effects of neuroinflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 284-293.	1.8	64
5	The Peritoneal Cavity Is a Distinct Compartment of Angiogenic Molecular Mediators. <i>Journal of Surgical Research</i> , 2006, 134, 28-35.	0.8	15
6	Distributed model of peritoneal fluid absorption. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1862-H1874.	1.5	45
7	Is Intraperitoneal Pressure Important?. <i>Peritoneal Dialysis International</i> , 2006, 26, 317-319.	1.1	14
8	Peritoneal dialysis, membranes and beyond. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 571-576.	1.0	8
9	Effects of chronic cold exposure on the endothelin system. <i>Journal of Applied Physiology</i> , 2006, 100, 1719-1726.	1.2	36
10	Intraperitoneal fluid therapy: an alternative to intravenous treatment in a patient with limited vascular access. <i>Anaesthesia</i> , 2006, 61, 502-504.	1.8	6
11	Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. <i>Kidney International</i> , 2006, 69, 1518-1525.	2.6	147
12	In vivo determination of diffusive transport parameters in a superfused tissue. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, F1096-F1103.	1.3	17
13	Correlating structure with solute and water transport in a chronic model of peritoneal inflammation. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F232-F240.	1.3	29
14	Genetic AVP deficiency abolishes cold-induced diuresis but does not attenuate cold-induced hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F1472-F1477.	1.3	26
15	Lymphatic Endothelial Cells, Lymphangiogenesis, and Extracellular Matrix. <i>Lymphatic Research and Biology</i> , 2006, 4, 83-100.	0.5	106
16	Mean Transit Time and Mean Residence Time for Linear Diffusionâ€“Convectionâ€“Reaction Transport System. <i>Computational and Mathematical Methods in Medicine</i> , 2007, 8, 37-49.	0.7	6
17	<i>Clostridium sordellii</i> Lethal Toxin Kills Mice by Inducing a Major Increase in Lung Vascular Permeability. <i>American Journal of Pathology</i> , 2007, 170, 1003-1017.	1.9	56
18	Ultrafiltration and Absorption in Evaluating Aquaporin Function from Peritoneal Transport of Sodium. <i>Peritoneal Dialysis International</i> , 2007, 27, 687-690.	1.1	8
19	Feasibility of Mesothelial Transplantation during Experimental Peritoneal Dialysis and Peritonitis. <i>International Journal of Artificial Organs</i> , 2007, 30, 513-519.	0.7	6

#	ARTICLE	IF	CITATIONS
20	Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 137-147.	2.0	18
21	Pathogenesis and treatment of peritoneal membrane failure. <i>Pediatric Nephrology</i> , 2008, 23, 695-703.	0.9	44
22	Peritoneal membrane recruitment in rats: a micro-computerized tomography ( $\hat{1}/4$ CT) study. <i>Pediatric Nephrology</i> , 2008, 23, 2179-2184.	0.9	4
23	Clinical application of aquaporin research: aquaporin-1 in the peritoneal membrane. <i>Pflugers Archiv European Journal of Physiology</i> , 2008, 456, 721-727.	1.3	14
24	Feasibility of complementary spatial modulation of magnetization tagging in the rat heart after manganese injection. <i>NMR in Biomedicine</i> , 2008, 21, 15-21.	1.6	12
25	Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2008, 15, 535-541.	0.7	74
26	Association Between Arterial Stiffness and Peritoneal Small Solute Transport Rate. <i>Artificial Organs</i> , 2008, 32, 416-419.	1.0	11
27	Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. <i>Acta Anaesthesiologica Scandinavica</i> , 2008, 52, 243-248.	0.7	5
28	Association between Arterial Stiffness and Peritoneal Fluid Kinetics. <i>American Journal of Nephrology</i> , 2008, 28, 128-132.	1.4	13
29	RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H1880-H1887.	1.5	33
30	Water and solute transport in peritoneal dialysis: models and clinical applications. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2120-2123.	0.4	18
31	Peritoneal morphological and functional changes associated with platelet-derived growth factor B. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 448-457.	0.4	11
32	Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F1084-F1093.	1.3	45
33	Endothelial Glycocalyx and the Peritoneal Barrier. <i>Peritoneal Dialysis International</i> , 2008, 28, 6-12.	1.1	51
34	In Vivo Peritoneal Surface Area Measurement in Rats by Micro-Computed Tomography ( $\hat{1}/4$ CT). <i>Peritoneal Dialysis International</i> , 2008, 28, 188-194.	1.1	9
35	Water and Solute Transport through Different Types of Pores in Peritoneal Membrane in Capd Patients with Ultrafiltration Failure. <i>Peritoneal Dialysis International</i> , 2009, 29, 664-669.	1.1	14
36	Inflammatory ascites formation induced by macromolecules in mice and rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 297, R218-R223.	0.9	6
37	Distributed modeling of osmotically driven fluid transport in peritoneal dialysis: theoretical and computational investigations. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H1960-H1968.	1.5	30

#	ARTICLE	IF	CITATIONS
39	Peritoneal dialysis prescription in children: bedside principles for optimal practice. <i>Pediatric Nephrology</i> , 2009, 24, 1633-1642.	0.9	73
40	Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 1-9.	2.0	48
41	Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan <i>in vitro</i> and peritoneal metastasis <i>in vivo</i> . <i>Cancer Science</i> , 2009, 100, 770-777.	1.7	51
42	Multiscale Measurements Distinguish Cellular and Interstitial Hindrances to Diffusion <i>In Vivo</i> . <i>Biophysical Journal</i> , 2009, 97, 330-336.	0.2	71
43	Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis. <i>Cirug�a Espa�ola (English Edition)</i> , 2009, 85, 3-13.	0.1	2
44	Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 216-224.	1.0	81
45	Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy. <i>Current Drug Discovery Technologies</i> , 2009, 6, 72-81.	0.6	36
46	Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN. <i>Journal of Immunotherapy</i> , 2010, 33, 8-15.	1.2	26
47	Pharmacology of perioperative 5-Fluorouracil. <i>Journal of Surgical Oncology</i> , 2010, 102, 730-735.	0.8	34
48	Hyperthermic intraperitoneal chemotherapy: Rationale and technique. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 68.	0.8	211
49	Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F721-F733.	1.3	66
50	Strategies for Improving Long-Term Survival in Peritoneal Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1123-1131.	2.2	42
51	Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis. <i>Science Signaling</i> , 2010, 3, ra55.	1.6	209
52	Abdominal Adhesion Prevention: Still a Sticky Subject. <i>Digestive Surgery</i> , 2010, 27, 347-358.	0.6	63
53	Competitive antagonism of fluorescent gentamicin uptake in the cochlea. <i>Hearing Research</i> , 2010, 268, 250-259.	0.9	23
54	Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2011, 2, 281-298.	3.3	491
55	Distributed Models of Peritoneal Transport. , 2011, , .		0
56	Docetaxel Distribution Following Intraperitoneal Administration in Mice. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 90.	0.9	12

#	ARTICLE	IF	CITATIONS
57	Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments. <i>Surgical Oncology</i> , 2011, 20, e38-e54.	0.8	90
58	Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 147-156.	1.1	52
59	Growing a peritoneal dialysis program: A single-center experience. <i>Dialysis and Transplantation</i> , 2011, 40, 343-348.	0.2	3
60	Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2322-2332.	0.4	33
61	Encapsulating peritoneal sclerosis: the state of affairs. <i>Nature Reviews Nephrology</i> , 2011, 7, 528-538.	4.1	90
62	Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F1331-F1341.	1.3	32
63	Adhesions during and after Surgical Procedures, their Prevention and Impact on Women'S Health. <i>Women's Health</i> , 2012, 8, 495-498.	0.7	15
64	Recent advances in drug delivery strategies for treatment of ovarian cancer. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 567-583.	2.4	39
65	Pharmacology of Perioperative Intraperitoneal and Intravenous Chemotherapy in Patients with Peritoneal Surface Malignancy. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 577-597.	0.6	39
66	Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 895-911.	1.1	23
67	Suppression of ConA-induced inflammatory ascites by lipopolysaccharide (LPS) in mice. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2012, 59, 387-392.	0.4	1
68	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. <i>Journal of Controlled Release</i> , 2012, 158, 379-385.	4.8	29
69	Intraperitoneal delivery of nanoparticles for cancer gene therapy. <i>Future Oncology</i> , 2013, 9, 59-68.	1.1	32
70	Peritoneal Fluid Transport: Mechanisms, Pathways, Methods of Assessment. <i>Archives of Medical Research</i> , 2013, 44, 576-583.	1.5	19
71	Quercetin Liposome Sensitizes Colon Carcinoma to Thermochemotherapy and Thermochemotherapy in Mice Models. <i>Integrative Cancer Therapies</i> , 2013, 12, 264-270.	0.8	25
72	Brain-targeted polymeric nanoparticles: <i>in vivo</i> evidence of different routes of administration in rodents. <i>Nanomedicine</i> , 2013, 8, 1373-1383.	1.7	26
73	Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 553-559.	0.7	9
74	Peritoneal Dialysis: Misperceptions and Reality. <i>American Journal of the Medical Sciences</i> , 2014, 348, 250-261.	0.4	9

#	ARTICLE	IF	CITATIONS
75	Is the Systemic Microvascular Endothelial Glycocalyx in Peritoneal Dialysis Patients Related to Peritoneal Transport?. <i>Nephron Clinical Practice</i> , 2014, 128, 159-165.	2.3	10
76	Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy. <i>AAPS Journal</i> , 2014, 16, 424-439.	2.2	29
77	Single compartment drug delivery. <i>Journal of Controlled Release</i> , 2014, 190, 157-171.	4.8	46
78	The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary. <i>Human Reproduction Update</i> , 2014, 20, 217-230.	5.2	243
79	A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats. <i>Pharmaceutical Research</i> , 2014, 31, 2876-2886.	1.7	11
80	Metastatic Colorectal Cancer: Survival Comparison of Hepatic Resection Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2667-2674.	0.7	26
81	Enzymatic tumour tissue digestion coupled to SPEâ€“UPLCâ€“Tandem Mass Spectrometry as a tool to explore paclitaxel tumour penetration. <i>Talanta</i> , 2014, 129, 119-125.	2.9	4
82	Miscellaneous conditions of the peritoneal cavityâ€“Peritoneal tumors, pseudomyxoma, mesothelioma, fibroblastic reaction, cocoon, cystic lymphatic malformations, blue-bleb, and chylous ascites. <i>Seminars in Pediatric Surgery</i> , 2014, 23, 363-368.	0.5	1
84	Modulation of ConA-induced inflammatory ascites by histamine â€“ Short communication. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2015, 62, 87-91.	0.4	2
85	Role of Spironolactone Chalcone in the Prevention of Peritoneal Fibrosis in Patients with Peritoneal Dialysis. <i>Tropical Journal of Pharmaceutical Research</i> , 2015, 14, 1893.	0.2	0
86	Fluvastatin inhibits the expression of fibronectin in human peritoneal mesothelial cells induced by high-glucose peritoneal dialysis solution via SGK1 pathway. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 336-342.	0.7	5
87	Effect of Irradiation on Tissue Penetration Depth of Doxorubicin after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel Ex-Vivo Model. <i>Journal of Cancer</i> , 2016, 7, 910-914.	1.2	26
88	Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. <i>Pleura and Peritoneum</i> , 2016, 1, 209-215.	0.5	11
89	Pharmacokinetic problems in peritoneal drug administration: an update after 20 years. <i>Pleura and Peritoneum</i> , 2016, 1, 183-191.	0.5	12
90	Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective. <i>European Journal of Hospital Pharmacy</i> , 2016, 23, 233-238.	0.5	3
91	Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 104, 251-259.	2.0	35
92	Preventing recurrence of diffuse malignant peritoneal mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 989-995.	1.1	5
93	The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis. <i>Stem Cells Translational Medicine</i> , 2016, 5, 235-247.	1.6	29

#	ARTICLE	IF	CITATIONS
94	Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2275-2280.	1.2	65
95	Oxidative Stress and Nuclear Factor $\kappa$ B (NF- $\kappa$ B) Increase Peritoneal Filtration and Contribute to Ascites Formation in Nephrotic Syndrome. <i>Journal of Biological Chemistry</i> , 2016, 291, 11105-11113.	1.6	11
96	Synthesis of Amphiphilic Poly( $\beta$ -amino ester) for Efficiently Minicircle DNA Delivery in Vivo. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 19284-19290.	4.0	22
97	Induction Chemotherapy. , 2016, , .		3
98	Infusoabdomen with abdominal compartment in extremely low birth weight neonates. <i>Journal of Pediatric Surgery Case Reports</i> , 2016, 6, 9-12.	0.1	1
99	Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). <i>Annals of Surgical Oncology</i> , 2016, 23, 1220-1224.	0.7	53
100	Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 1916-1922.	0.7	23
101	Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule. <i>Drug Delivery</i> , 2017, 24, 491-501.	2.5	64
102	Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Clinical and Experimental Metastasis</i> , 2017, 34, 309-314.	1.7	55
103	Strategies to Target Glucose Metabolism in Tumor Microenvironment on Cancer by Flavonoids. <i>Nutrition and Cancer</i> , 2017, 69, 534-554.	0.9	18
104	Pharmacological principles of intraperitoneal and bidirectional chemotherapy. <i>Pleura and Peritoneum</i> , 2017, 2, 47-62.	0.5	53
105	Liposome-supported enzymatic peritoneal dialysis. <i>Biomaterials</i> , 2017, 145, 128-137.	5.7	18
106	Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 841-850.	1.1	11
107	A novel method to deplete $\beta$ -lactam antibiotic residues by administration of a broad-spectrum $\beta$ -lactamase enzyme in fish tissues. <i>Fisheries and Aquatic Sciences</i> , 2017, 19, .	0.3	0
108	Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis "Mission possible?". <i>Advanced Drug Delivery Reviews</i> , 2017, 108, 13-24.	6.6	76
109	Combination Treatment of Citral Potentiates the Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with Pirarubicin for Colorectal Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 3588-3597.	2.3	6
110	Modelling drug transport during intraperitoneal chemotherapy. <i>Pleura and Peritoneum</i> , 2017, 2, 73-83.	0.5	18
111	Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotherpy to treat patients with peritoneal carcinomatosis. <i>Oncotarget</i> , 2017, 8, 78208-78224.	0.8	18

#	ARTICLE	IF	CITATIONS
112	Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 481-494.	2.4	24
113	HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?. , 2018, , 79-102.		0
114	Effect of sensor location on continuous intraperitoneal glucose sensing in an animal model. <i>PLoS ONE</i> , 2018, 13, e0205447.	1.1	12
115	Feasibility and Characteristics of Pressurized Aerosol Chemotherapy (PAC) in the Bladder as a Therapeutic Option in Early-stage Urinary Bladder Cancer. <i>In Vivo</i> , 2018, 32, 1369-1372.	0.6	11
116	Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis. <i>Pleura and Peritoneum</i> , 2018, 3, 20180103.	0.5	36
117	Electric cauterization of the hernia sac in laparoscopic ventral hernia repair reduces the incidence of postoperative seroma: a propensity score-matched analysis. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2018, 22, 747-750.	0.9	9
118	Mediation of inflammatory ascites formation induced by macromolecules in mice. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2018, 65, 151-162.	0.4	1
120	Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy. <i>Journal of Cancer</i> , 2018, 9, 13-20.	1.2	32
121	New Treatment Modalities for the Management of Peritoneal Metastases. , 2018, , 469-506.		4
122	Differences in peritoneal solute transport rates in peritoneal dialysis. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 122-134.	0.7	10
123	Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. <i>Oncotarget</i> , 2019, 10, 1407-1424.	0.8	17
124	Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis. <i>Cancers</i> , 2019, 11, 906.	1.7	18
125	Why intraperitoneal glucose sensing is sometimes surprisingly rapid and sometimes slow: A hypothesis. <i>Medical Hypotheses</i> , 2019, 132, 109318.	0.8	4
126	The use of intraperitoneal chemotherapy for gastric malignancies. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 879-888.	1.1	20
127	Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 1394-1400.	0.7	37
128	Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. <i>Journal of Surgical Oncology</i> , 2019, 119, 999-1010.	0.8	23
129	A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy. <i>Drug Delivery</i> , 2019, 26, 404-415.	2.5	35
130	Murine Models of Intraperitoneal Perfusion for Disseminated Colorectal Cancer. <i>Journal of Surgical Research</i> , 2019, 233, 310-322.	0.8	8



#	ARTICLE	IF	CITATIONS
131	Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. <i>ACS Nano</i> , 2020, 14, 255-271.	7.3	100
132	Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. <i>Drug Delivery</i> , 2020, 27, 40-53.	2.5	53
133	Enabling Microparticle Imprinting to Achieve Penetration and Local Endurance in the Peritoneum via High-Intensity Ultrasound (HIUS) for the Treatment of Peritoneal Metastasis. <i>International Journal of Surgical Oncology</i> , 2020, 2020, 1-7.	0.3	5
134	On the change of transport parameters with dwell time during peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2021, 41, 404-412.	1.1	2
135	Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery: A Clinical Practice Guideline. <i>Current Oncology</i> , 2020, 27, 146-154.	0.9	22
136	Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels. <i>Scientific Reports</i> , 2020, 10, 13735.	1.6	12
137	An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1479-1492.	0.9	8
138	Impact of Perfusate Concentration on Hyperthermic Intraperitoneal Chemotherapy Efficacy and Toxicity in a Rodent Model. <i>Journal of Surgical Research</i> , 2020, 253, 262-271.	0.8	6
139	Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy. <i>Pharmaceutical Research</i> , 2020, 37, 119.	1.7	8
140	Evaluation of a Novel Prototype for Pressurized Intraperitoneal Aerosol Chemotherapy. <i>Cancers</i> , 2020, 12, 633.	1.7	9
141	Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4963-4969.	0.7	12
142	Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. <i>European Journal of Cancer</i> , 2020, 127, 76-95.	1.3	61
143	A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes. <i>Journal of Controlled Release</i> , 2020, 320, 431-441.	4.8	4
144	Is Prophylactic Hyperthermic Intraperitoneal Chemotherapy Beneficial to the Long-Term Survival of Patients After Radical Gastric Cancer Surgery: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
145	Advancement of Biomaterial-Based Postoperative Adhesion Barriers. <i>Macromolecular Bioscience</i> , 2021, 21, e2000395.	2.1	58
146	Application of IPC, HIPEC, and PIPAC. , 2021, , 111-133.		0
147	Technical Aspects and Prescription of Peritoneal Dialysis in Children. , 2021, , 193-228.		1
148	HIPEC Methodology and Regimens: The Need for an Expert Consensus. <i>Annals of Surgical Oncology</i> , 2021, 28, 9098-9113.	0.7	22

#	ARTICLE	IF	CITATIONS
149	Intraperitoneal Drug Therapy: Physical and Biological Principles. , 2007, 134, 131-152.		12
150	Principles of Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. , 2007, 169, 39-51.		35
151	Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura and Peritoneum, 2020, 5, 20200137.	0.5	9
153	Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World Journal of Gastrointestinal Oncology, 2010, 2, 19.	0.8	48
154	Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2022, 29, 2077-2086.	0.7	5
155	Progress in Peritoneal Dialysis. , 2011, , .		0
156	Technical Aspects and Prescription of Peritoneal Dialysis in Children. , 2012, , 169-203.		1
157	Abdominal Advanced Oncologic Surgery. , 0, , .		0
158	Principles and Innovations in Peritoneal Surface Malignancy Treatment. World Journal of Oncology, 2013, 4, 129-136.	0.6	6
159	Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. World Journal of Obstetrics and Gynecology, 2013, 2, 143.	0.5	1
160	Zytoreduktive Chirurgie und Hypertherme Intraperitoneale Chemotherapie (HIPEC). , 2013, , 165-185.		0
161	Kinetic Modeling of Peritoneal Dialysis. Studies in Computational Intelligence, 2013, , 1427-1475.	0.7	0
162	Cytoreductive Surgery and "Hyperthermic Intraperitoneal Chemotherapy (HIPEC)", 2016, , 187-211.		0
163	Encapsulating Peritoneal Sclerosis: Case report and Current Status. Archives of Clinical Nephrology, 0, , 039-046.	0.1	0
164	Applikation von IPC, HIPEC und PIPAC. , 2018, , 119-141.		0
165	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on the Electrolytes Changes and Nefropaty. Biomedical Journal of Scientific & Technical Research, 2018, 3, .	0.0	0
166	The Basis of Regional Therapy, Pharmacology, Hyperthermia, and Drug Resistance. , 2020, , 3-15.		0
167	The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. Biomedicines, 2021, 9, 1554.	1.4	2

#	ARTICLE	IF	CITATIONS
168	Physiologic Influences of Transepithelial K <sup>+</sup> Secretion. <i>Physiology in Health and Disease</i> , 2020, , 337-393.	0.2	0
169	Ideal Nozzle Position During Pressurized Intraperitoneal Aerosol Chemotherapy in an <i>Ex Vivo</i> Model. <i>Anticancer Research</i> , 2021, 41, 5489-5498.	0.5	6
170	Diffusion p <sub>eritonéale</sub> des antibiotiques. , 2007, , 41-50.		0
171	Place de la chimiothérapie intrap <sub>eritonéale</sub> (NIPS, EPIC, PIPAC, CHIP). <i>Colon and Rectum</i> , 2020, 14, 193-199.	0.0	0
172	The Effects of Acute Blood Loss for Diagnostic Bloodwork and Fluid Replacement in Clinically Ill Mice. <i>Comparative Medicine</i> , 2015, 65, 202-16.	0.4	1
173	Anesthetic implications in hyperthermic intraperitoneal chemotherapy. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2019, 35, 3-11.	0.2	5
174	The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. <i>Pharmaceutics</i> , 2021, 13, 2043.	2.0	5
175	Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy. <i>Visceral Medicine</i> , 2022, 38, 109-119.	0.5	2
176	Le p <sub>eritoine</sub> : une membrane filtrante. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2022, 206, 187-194.	0.0	0
177	Anesthetic implications in hyperthermic intraperitoneal chemotherapy. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2019, 35, 3.	0.2	11
178	Prophylactic hyperthermic intraperitoneal chemotherapy may benefit the long-term survival of patients after radical gastric cancer surgery. <i>Scientific Reports</i> , 2022, 12, 2583.	1.6	9
179	Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the Treatment of Pancreatic Cancer. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 10015-10029.	4.0	3
180	The Peritoneal Membraneâ€”A Potential Mediator of Fibrosis and Inflammation among Heart Failure Patients on Peritoneal Dialysis. <i>Membranes</i> , 2022, 12, 318.	1.4	4
181	Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121828.	2.6	7
182	Advances in the management of peritoneal malignancies. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 698-718.	12.5	20
184	Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies. <i>Drugs</i> , 2023, 83, 159-180.	4.9	4